RPS17

Across TCGA pan-cancer cohorts, RPS17 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RPS17’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPS17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPS17 is over-expressed in tumor, although a few such as BRCA and UCEC show the opposite, repressed pattern.

KIRC, LIHC, and BRCA are the cancer types where RPS17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.644	<.001	12	view →
LIHC	All	II,III,IV	+0.889	<.001	8	view →
BRCA	Female	II,III,IV	−0.449	<.001	6	view →
KIRP	Male	All	+0.414	.005	6	view →
CHOL	Male	All	+2.021	<.001	5	view →
COAD	All	All	+0.417	<.001	5	view →
LUSC	Male	All	+0.497	<.001	4	view →
HNSC	Male	IV	+0.682	.039	2	view →
UCEC	All	All	−0.381	.042	2	view →
KICH	Male	II,III,IV	+0.790	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RPS17–KIRC

Open the KIRC breakdown →